Back to search
FDAFDA · Food and drugs·Recall number D-0063-2023

Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals Inc. Morgantown, WV 36505, Made in India, NDC 0378-3634-05

Published November 23, 2022 · Recall initiated: October 21, 2022

Summary

FDA records drug Class II recall D-0063-2023, published November 23, 2022 and initiated October 21, 2022. Recalling firm: Viatris Inc; Status: Terminated; Reported quantity: 2,794 bottles; Lot: Lot #: 3150116, Exp 2/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Viatris Inc
Distributor
Nationwide in the USA
Lot
Lot #: 3150116, Exp 2/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Carvedilol Tablets, USP, 25 mg, 500-count bottles, Rx Only, Mfg: Mylan Pharmaceuticals Inc. Morgantown, WV 36505, Made in India, NDC 0378-3634-05 recalled?

Yes. FDA published recall D-0063-2023 on November 23, 2022. Reported hazard: Failed Tablet/Capsule Specifications: Tablets exceeds specification for weight and thickness.

What should I do if I have this product?

Voluntary: Firm initiated · Letter